Skip to content
TrialMatch
Sign up
Recruiting Phase 1 / Phase 2

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Create a profile to match View the full record on ClinicalTrials.gov

About this study

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Condition
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Tested
RMC-6236
Sponsor
Revolution Medicines, Inc.

Who can join

Age
18 years and older
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 6

  • Minimum age: 18 years
  • Study condition: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
  • Histologically confirmed advanced solid tumor with specific KRAS G12 mutations (dose escalation) or RAS mutations (dose optimization/expansion) identified through deoxyribonucleic acid (DNA) sequencing. PDAC with wild-type RAS (expansion).
  • Treatment naive or have received prior standard therapy appropriate for tumor type and stage
  • Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Adequate organ function

Exclusion 5

  • Primary central nervous system (CNS) tumors
  • Active, untreated brain metastases
  • Known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication
  • History of any other unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a participant, impact their expected survival through the end of the study participation, and/or impact their ability to comply with the protocol prior/concomitant therapy
  • Other inclusion/exclusion criteria may apply.

Where

21 sites, 21 recruiting

Piedmont Healthcare

Atlanta, Georgia, United States

Recruiting

University of Texas at Austin

Austin, Texas, United States

Recruiting

Johns Hopkins University

Baltimore, Maryland, United States

Recruiting

Mary Bird Perkins Cancer Center

Baton Rouge, Louisiana, United States

Recruiting

Dana Farber Cancer Institute

Boston, Massachusetts, United States

Recruiting

Tennessee Oncology

Chattanooga, Tennessee, United States

Recruiting

and 15 more sites on ClinicalTrials.gov

Contact

Potential match only. Final eligibility is determined by the study team.